Izzedine Hassane, Isnard-Bagnis Corinne, Hulot Jean Sébastien, Vittecoq Daniel, Cheng Andrew, Jais Carmen Kreft, Launay-Vacher Vincent, Deray Gilbert
Department of Nephrology, Pitie-Salpêtrière Hospital, Paris, France.
AIDS. 2004 Apr 30;18(7):1074-6. doi: 10.1097/00002030-200404300-00019.
The safety of tenovir disoproxil fumarate (TDF) was assessed in two double-blind, placebo-controlled studies. Furthermore, we retrospectively collected 19 cases of TDF-associated tubular dysfunction. The incidence of renal events was similar among the active TDF groups and the placebo group in the two double-blind, placebo-controlled studies. Proximal tubulopathy was diagnosed 6.89 +/- 5.51 months after TDF therapy started. All abnormalities normalized within 4.7 +/- 2.94 weeks after drug discontinuation.
在两项双盲、安慰剂对照研究中评估了替诺福韦酯（TDF）的安全性。此外，我们回顾性收集了19例与TDF相关的肾小管功能障碍病例。在两项双盲、安慰剂对照研究中，活性TDF组和安慰剂组的肾脏事件发生率相似。近端肾小管病在TDF治疗开始后6.89±5.51个月被诊断出来。停药后4.7±2.94周内所有异常均恢复正常。
